{
  "id": "lag-three",
  "title": "LAG-3",
  "lang": "en",
  "source_lang": "en",
  "summary": "LAG-3 is an inhibitory immune receptor that regulates T-cell responses and is a target of cancer immunotherapy.",
  "category": "science",
  "subcategory": "biology",
  "type": "concept",
  "aliases": [
    "Lymphocyte activation gene 3 protein",
    "Lymphocyte-activation gene 3",
    "CD223"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/lag-three/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/lag-three/",
      "json": "https://aiwiki.page/zh/lag-three.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "LAG-3 is a cell-surface protein that helps restrain immune responses, particularly those mediated by T cells. Encoded by the human LAG3 gene, it belongs to the immunoglobulin superfamily and functions as an inhibitory immune checkpoint. Its expression commonly increases after lymphocyte activation and can remain elevated during prolonged antigen exposure. LAG-3 contributes to immune regulation but can also limit antitumor immune responses, making it a target of cancer immunotherapy."
    },
    {
      "heading": "Discovery and molecular structure",
      "text": "LAG-3 was identified in 1990 through studies of activated human lymphocytes. Its name reflects its discovery as a gene associated with lymphocyte activation, rather than indicating that its protein product simply stimulates immune activity. The human gene lies on chromosome 12 near the gene encoding CD4, a structurally related immune-cell surface protein.\n\nThe human LAG-3 precursor contains 525 amino acids. It has four extracellular immunoglobulin-like domains, a single segment spanning the cell membrane, and a cytoplasmic tail. Its extracellular region undergoes glycosylation. Despite structural similarities to CD4, LAG-3 has distinct ligand-binding properties and biological functions.\n\nLAG-3 does not contain the classical inhibitory signaling motifs found in several other immune receptors. Conserved sequences in its cytoplasmic tail are important for its activity, but its intracellular inhibitory mechanism is not fully resolved.\n\nCell-surface abundance is regulated by both intracellular trafficking and proteolytic cleavage. Cleavage by the enzymes ADAM10 and ADAM17 releases the extracellular portion as soluble LAG-3. Naturally shed LAG-3 and engineered soluble LAG-3 fusion proteins are distinct molecular forms and should not be assumed to have identical biological effects."
    },
    {
      "heading": "Expression and immune function",
      "text": "LAG-3 is expressed principally on activated immune cells, including subsets of CD4 and CD8 T cells, regulatory T cells, and natural killer cells. Its abundance varies with cell type, activation state, tissue environment, and duration of stimulation.\n\nIn conventional T cells, LAG-3 can reduce proliferation, cytokine production, and other responses to antigen stimulation. It therefore helps regulate the intensity and duration of immune activity. In some settings, it also contributes to the suppressive function of regulatory T cells and to immune tolerance.\n\nPersistent exposure to an antigen, as can occur in chronic infections and tumors, can produce a state termed T-cell exhaustion. Exhausted T cells exhibit altered functional, transcriptional, and metabolic states and frequently express multiple inhibitory receptors. LAG-3 often occurs alongside programmed cell death protein 1, commonly called PD-1, in these populations.\n\nLAG-3 expression alone does not establish that a cell is exhausted. Recently activated, functional T cells can also express it. Interpretation requires information about cell identity, other molecular markers, functional activity, and the surrounding tissue."
    },
    {
      "heading": "Ligands and inhibitory mechanisms",
      "text": "The best-established binding partner for LAG-3 is class II major histocompatibility complex molecules, or MHC class II. These molecules present peptides to CD4 T cells and are characteristically expressed by antigen-presenting cells. LAG-3 binding can depend on the structural state of the peptide–MHC class II complex.\n\nOther reported binding partners include fibrinogen-like protein 1, galectin-3, and LSECtin. Their relative contributions vary across experimental systems and biological contexts. No single ligand interaction necessarily explains all effects attributed to LAG-3.\n\nLAG-3 can influence signaling associated with the T-cell receptor. Its action is not adequately described as simple competition with CD4 for MHC class II: receptor organization, intracellular sequences, ligand availability, and the local cellular environment also matter. The detailed relationship between ligand binding and intracellular inhibition remains an active area of research.\n\nLAG-3 and PD-1 have overlapping but nonidentical functions. Experimental studies show that they can cooperate in limiting T-cell responses. This provides a biological rationale for blocking both pathways rather than treating them as interchangeable targets."
    },
    {
      "heading": "Role in cancer and therapeutic targeting",
      "text": "Within the microenvironment of some cancers, LAG-3 is expressed on tumor-infiltrating lymphocytes, including cells that also express PD-1. Inhibitory signaling can constrain immune responses against tumor antigens.\n\nLAG-3-blocking antibodies are designed to reduce this inhibition. Their mechanism differs from conventional drugs that directly damage tumor cells: they modify immune regulation and depend on the broader antitumor immune response.\n\nIn March 2022, the United States Food and Drug Administration approved the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and nivolumab, an anti-PD-1 antibody, for adults and adolescents aged 12 years or older with unresectable or metastatic melanoma. This was the first FDA approval of a LAG-3-blocking antibody. In the pivotal randomized controlled trial, the combination improved progression-free survival compared with nivolumab alone.\n\nCheckpoint blockade can cause immune-mediated adverse reactions involving organs such as the skin, intestine, liver, lungs, and endocrine glands. The clinical effects and safety of LAG-3-directed treatment depend on the particular drug, combination, cancer, and patient population; activity in one setting does not establish effectiveness in another."
    },
    {
      "heading": "Measurement and research limitations",
      "text": "LAG-3 can be examined using flow cytometry, tissue immunohistochemistry, and measurements of RNA or soluble protein. These approaches measure different aspects of its biology. Gene expression does not necessarily correspond directly to surface receptor abundance, and soluble LAG-3 concentrations do not directly measure inhibitory signaling within a tumor.\n\nIts use as a biomarker is complicated by heterogeneous expression, changes over time, and differences between laboratory assays. The percentage of LAG-3-positive cells also does not fully describe which cells express the receptor or whether those cells contribute to tumor control.\n\nResearch therefore distinguishes several related but separate questions: whether LAG-3 is present, whether it is functionally limiting an immune response, and whether blocking it improves a clinical outcome. Evidence for one does not automatically establish the others."
    }
  ],
  "links": [
    "protein",
    "t-cell",
    "gene",
    "immune-checkpoint",
    "amino-acid",
    "cell-membrane",
    "glycosylation",
    "regulatory-t-cell",
    "natural-killer-cell",
    "cytokine",
    "immune-tolerance",
    "antigen",
    "t-cell-exhaustion",
    "pd-one",
    "major-histocompatibility-complex",
    "antigen-presenting-cell",
    "t-cell-receptor",
    "cancer",
    "antibody",
    "melanoma",
    "randomized-controlled-trial",
    "flow-cytometry",
    "immunohistochemistry",
    "biomarker"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}